However, I think it was a strategic mistake setting expectations so high,” he said. New trial Martin Holst Lange, Novo ...

Martin Holst Lange, executive vice president for development at Novo Nordisk, said in a statement that the company was "encouraged" by the results. He added that with the insights from the trial ...

Despite these setbacks, Novo Nordisk said it remains committed to CagriSema ... both semaglutide and cagrilintide in ...

A phase 3 trial of Novo Nordisk’s next-generation obesity ... 25% on calls with investors throughout 2023 and 2024. Martin Holst Lange, executive vice president of development at Novo, repeated ...

This was achieved even though only 57% of patients reached the highest CagriSema dose,” said Martin Holst Lange, executive vice president for development at Novo Nordisk, in a statement Friday.

(CNN) — Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and ... in monotherapy,” Martin Holst Lange, executive vice president ...

This was achieved even though only 57% of patients reached the highest CagriSema dose,” said Martin Holst Lange, executive vice president for Development at Novo Nordisk. “With the insights ...

This was achieved even though only 57% of patients reached the highest CagriSema dose," Martin Holst Lange, executive vice president for development at Novo Nordisk, said in a separate press release.

Martin Holst Lange, Novo Nordisk’s executive vice president for development, said Novo was “encouraged” by the data. He said only 57% of patients in the trial reached the highest dose.

This was achieved even though only 57% of patients reached the highest CagriSema dose,” said Martin Holst Lange, executive vice president for development at Novo Nordisk, in a statement Friday. The ...